In an HD mouse model, knockout of A2 AR was shown to significantly worsen motor symptoms and survival [4], and treatment with a selective A2 AR agonist delayed the progression of motor phenotypes in transgenic HD mouse models and ameliorated huntingtin protein aggregation [5, 6]. This evidence concerns the gene ADORA2A and Huntington disease.